Search Results - "Barrier, Jocelyn"
-
1
Profile of Long-Term Survivors in Multiple Myeloma
Published in Blood (13-11-2019)“…Background: The treatment revolution of multiple myeloma (MM) with the advent of novel therapies, proteasome inhibitors, immunomodulators and newer drugs lead…”
Get full text
Journal Article -
2
Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma
Published in British journal of haematology (01-09-2019)Get full text
Journal Article -
3
Phase 1/2 Study of Orociep All Oral Regimen with Idarubicin, Cyclophosphamide, Etoposide, Prednisolone in Combination to Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma. Final Analysis
Published in Blood (08-12-2017)“…Background. CHOP, recently combined to the first in class anti CD20immunotherapy, is the leading regimen worldwide for the treatment of high grade B cell non…”
Get full text
Journal Article -
4
Chronic HCV Infection and Autologous Stem Cell Transplantation for Multiple Myeloma
Published in Blood (29-11-2018)“…Introduction. The pronostic of Chronic hepatitis C (Hep C) has transformed towards cure in recent years with the advent of the antiviral treatment by…”
Get full text
Journal Article -
5
Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma
Published in Blood (29-11-2018)“…Background. Triplet-based lenalidomide plus dexamethasone combinations have become the new standard of care for early RRMM, including with carfilzomib (KRd)…”
Get full text
Journal Article -
6
Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma
Published in Blood (08-12-2017)“…Background. Triplet-based lenalidomide plus dexamethasone combinations have become the new standard of care for early relapse and refractory multiple myeloma…”
Get full text
Journal Article -
7
Pomalidomide 3rd Line Versus 4th Line for RRMM
Published in Blood (08-12-2017)“…Background. Pomalidomide in association with dexamethasone is approved for RRMM in 3rd line and beyond based on the multicenter international phase 3MM-003…”
Get full text
Journal Article -
8
Carfilzomib weekly 20/56 mg/m 2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
Published in American journal of hematology (01-01-2019)Get full text
Journal Article -
9
Carfilzomib weekly 20/56 mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
Published in American journal of hematology (01-01-2019)Get full text
Journal Article -
10
Alterations in the ganglioside composition of rat cortical brain slices during experimental lactic acidosis: implication of an enzymatic process independent of the oxidative stress
Published in Biochimica et biophysica acta. General subjects (19-07-1997)“…Several in vitro studies have shown that lactic acidosis plays a role in brain damage by enhancing free radical formation and lipid peroxidation. The purpose…”
Get full text
Journal Article